Journal
CURRENT MEDICINAL CHEMISTRY
Volume 16, Issue 17, Pages 2189-2204Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986709788612710
Keywords
Metabotropic glutamate receptors (mGluRs); agonists and antagonists; anticonvulsive; anti-epileptogenic; glutamate-induced epileptic discharges
Funding
- National Medical Research Council [NMRC/0777/2003, NMRC/0960/2005, SHF/FG217P/2005]
- Edmund Safra Foundation
- Paul Hamlyn Foundation
Ask authors/readers for more resources
The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti-epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and anti-epileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation anti-epileptogenic and anticonvulsive drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available